NASDAQ:MEDP

Medpace Stock Forecast, Price & News

$158.62
-0.20 (-0.13 %)
(As of 05/11/2021 12:00 AM ET)
Add
Compare
Today's Range
$156.00
$161.22
50-Day Range
$157.36
$194.30
52-Week Range
$78.46
$196.12
Volume289,126 shs
Average Volume211,482 shs
Market Capitalization$5.71 billion
P/E Ratio48.51
Dividend YieldN/A
Beta1.35
30 days | 90 days | 365 days | Advanced Chart
Receive MEDP News and Ratings via Email

Sign-up to receive the latest news and ratings for Medpace and its competitors with MarketBeat's FREE daily newsletter.


Medpace logo

About Medpace

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services to the biotechnology, pharmaceutical, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MEDP
CUSIPN/A
Phone513-579-9911
Employees3,600
Year FoundedN/A

Sales & Book Value

Annual Sales$860.97 million
Cash Flow$4.28 per share
Book Value$20.16 per share

Profitability

Net Income$100.44 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap$5.71 billion
Next Earnings Date7/26/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.19 out of 5 stars

Medical Sector

946th out of 2,045 stocks

Commercial Physical Research Industry

18th out of 42 stocks

Analyst Opinion: 1.3Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Medpace (NASDAQ:MEDP) Frequently Asked Questions

Is Medpace a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Medpace stock.
View analyst ratings for Medpace
or view top-rated stocks.

What stocks does MarketBeat like better than Medpace?

Wall Street analysts have given Medpace a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Medpace wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Medpace's next earnings date?

Medpace is scheduled to release its next quarterly earnings announcement on Monday, July 26th 2021.
View our earnings forecast for Medpace
.

How were Medpace's earnings last quarter?

Medpace Holdings, Inc. (NASDAQ:MEDP) released its earnings results on Sunday, April, 25th. The company reported $1.14 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.01 by $0.13. The company had revenue of $260 million for the quarter, compared to analysts' expectations of $266.48 million. Medpace had a net margin of 13.87% and a trailing twelve-month return on equity of 17.67%. The company's revenue for the quarter was up 12.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.76 EPS.
View Medpace's earnings history
.

How has Medpace's stock price been impacted by Coronavirus (COVID-19)?

Medpace's stock was trading at $83.64 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, MEDP shares have increased by 89.6% and is now trading at $158.62.
View which stocks have been most impacted by COVID-19
.

What guidance has Medpace issued on next quarter's earnings?

Medpace updated its FY 2021 earnings guidance on Tuesday, May, 4th. The company provided EPS guidance of 4.240-4.420 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.370. The company issued revenue guidance of $1.09 billion-$1.15 billion, compared to the consensus revenue estimate of $1.14 billion.

What price target have analysts set for MEDP?

4 equities research analysts have issued 1-year price objectives for Medpace's stock. Their forecasts range from $83.00 to $181.00. On average, they anticipate Medpace's stock price to reach $131.80 in the next twelve months. This suggests that the stock has a possible downside of 16.9%.
View analysts' price targets for Medpace
or view top-rated stocks among Wall Street analysts.

Who are Medpace's key executives?

Medpace's management team includes the following people:
  • Dr. August James Troendle, Chairman, Pres & CEO (Age 65, Pay $1.13M)
  • Mr. Jesse J. Geiger, CFO & COO of Laboratory Operations (Age 47, Pay $678.19k)
  • Ms. Susan E. Burwig, Exec. VP of Operations (Age 58, Pay $750.25k)
  • Mr. Stephen P. Ewald, Chief Compliance Officer, Gen. Counsel & Corp. Sec. (Age 52, Pay $587.56k)
  • Mr. Todd Meyers, VP of Bus. Devel. & Marketing
  • Mr. Weimin Gai MS, Sr. VP of Biometrics
  • Mr. Daniel O'Leary, Sr. VP of Medical Department
  • John T. Wynne, Sr. VP of Commercial Operations & Clinical Pharmacology Unit

What is August Troendle's approval rating as Medpace's CEO?

268 employees have rated Medpace CEO August Troendle on Glassdoor.com. August Troendle has an approval rating of 34% among Medpace's employees. This puts August Troendle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Medpace's key competitors?

What other stocks do shareholders of Medpace own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), Exact Sciences (EXAS), Square (SQ), Baidu (BIDU), JD.com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Alibaba Group (BABA), Cisco Systems (CSCO) and Intuitive Surgical (ISRG).

When did Medpace IPO?

(MEDP) raised $150 million in an IPO on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

What is Medpace's stock symbol?

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

Who are Medpace's major shareholders?

Medpace's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (10.76%), Wasatch Advisors Inc. (7.38%), Boston Trust Walden Corp (1.51%), Standard Life Aberdeen plc (1.06%), GW&K Investment Management LLC (0.97%) and Fisher Asset Management LLC (0.82%). Company insiders that own Medpace stock include August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Stephen P Ewald and Susan E Burwig.
View institutional ownership trends for Medpace
.

Which major investors are selling Medpace stock?

MEDP stock was sold by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Acadian Asset Management LLC, Tributary Capital Management LLC, Los Angeles Capital Management LLC, Smith Asset Management Group LP, Royce & Associates LP, Chevy Chase Trust Holdings Inc., and The Manufacturers Life Insurance Company . Company insiders that have sold Medpace company stock in the last year include August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Stephen P Ewald, and Susan E Burwig.
View insider buying and selling activity for Medpace
or view top insider-selling stocks.

Which major investors are buying Medpace stock?

MEDP stock was purchased by a variety of institutional investors in the last quarter, including Riverbridge Partners LLC, Standard Life Aberdeen plc, BlackRock Inc., Strs Ohio, Premier Fund Managers Ltd, GW&K Investment Management LLC, Boston Trust Walden Corp, and Victory Capital Management Inc..
View insider buying and selling activity for Medpace
or or view top insider-buying stocks.

How do I buy shares of Medpace?

Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Medpace's stock price today?

One share of MEDP stock can currently be purchased for approximately $158.62.

How much money does Medpace make?

Medpace has a market capitalization of $5.71 billion and generates $860.97 million in revenue each year. The company earns $100.44 million in net income (profit) each year or $3.02 on an earnings per share basis.

How many employees does Medpace have?

Medpace employs 3,600 workers across the globe.

What is Medpace's official website?

The official website for Medpace is www.medpace.com.

Where are Medpace's headquarters?

Medpace is headquartered at 5375 MEDPACE WAY, CINCINNATI OH, 45227.

How can I contact Medpace?

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at 513-579-9911 or via email at [email protected]


This page was last updated on 5/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.